Skip to main navigation Skip to search Skip to main content

A Phase 2 Open Label Pilot Study to Evaluate the Safety and Efficacy of Subcutaneously Administered ELX-02 in Patients with Alport Syndrome with Col4A5 and Col4A3/4 Nonsense Mutation

  • Kerr, Peter (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date5/12/22 → 4/12/27

Clinical Trial Phase

  • Phase II